Mark DeLong
Corporate Officer/Principal chez APELLIS PHARMACEUTICALS, INC.
Fortune : 2 M $ au 31/05/2024
Profil
Mark DeLong is currently the Chief Business & Strategy Officer at Apellis Pharmaceuticals, Inc. He previously worked at EMD Serono, Inc. as the Head of Business Development from 2007 to 2018.
Mr. DeLong completed his undergraduate degree at The Pennsylvania State University and holds an MBA from the University of Michigan.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 18/03/2024 | 54 693 ( 0,05% ) | 2 M $ | 31/05/2024 |
Postes actifs de Mark DeLong
| Sociétés | Poste | Début |
|---|---|---|
| APELLIS PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/02/2018 |
Anciens postes connus de Mark DeLong
| Sociétés | Poste | Fin |
|---|---|---|
EMD Serono, Inc.
 EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Corporate Officer/Principal | 01/01/2018 |
Formation de Mark DeLong
| The Pennsylvania State University | Undergraduate Degree |
| University of Michigan | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| APELLIS PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
EMD Serono, Inc.
EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Health Technology |
